Imaging Modalities

The key to success is in appropriate options.


The inclusion of the appropriate imaging modality makes for a more efficient trial. For this reason, ACR Image Metrix™ consults with you about your trial to determine the most suitable imaging options and combinations to reflect established biomarkers and endpoints. With our available modalities in conventional imaging, novel imaging and nuclear medicine and access to our network of imaging experts, your trial will have the necessary tools for your investigation.


Modalities
Conventional Imaging:

  1. X-Ray Imaging
  2. Magnetic Resonance Imaging (MRI)
  3. Computed Tomography (CT)
  4. Ultrasonography
  5. Nuclear Medicine
  6. Vascular and Interventional Radiology

Novel Imaging-MRI Based:

  1. Blood Oxygen Level Dependent (BOLD) MRI Imaging
  2. Magnetic Resonance Spectroscopy (MRS)
  3. Magnetic Resonance Angiography (MRA)
  4. Dynamic Contrast-Enhanced MRI (DCE-MRI)
  5. Diffusion Weighted Imaging (DWI) and Diffusion Tensor Imaging (DTI)
  6. Magnetic Resonance Elastography (MRE)
  7. High-Field MRI

Nuclear Medicine:

  1. 18F-Fluorothymidine (FLT)
  2. 18F-Flouromisonidazol (FMISO)
  3. 11-C-Methionine (MET)
  4. 64Cu-Diacetyl-Bis (N4-methylthiosemicarbazone) (Cu-ATSM)
  5. Beta-Amyloid Imaging

This list of imaging modalities continues to be developed and refined through new technology, SOPs and training; its extensive applications provide the answer to obstacles you may face with your pharmaceutical, biotech or medical device trial. However, when incorporating imaging into a development program, it is essential to remember that each trial possesses distinct conditions under which appropriate imaging must be selected. ACR Image Metrix individually reviews projects to ensure that your trial receives the modality or modalities necessary to effectively achieve your goals.